Infinity Pharmaceuticals Inc. INFI

NAS: INFI | ISIN: US45665G3039   30/11/2023
0,004 USD (+20,00%)
(+20,00%)   30/11/2023

Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!

NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI) and certain of its officers. 

Class Definition:

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Infinity securities between January 5, 2023 and July 24, 2023, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/infi.

Case Details:

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Infinity overstated its prospects for a breast cancer treatment; (2) Infinity was overly optimistic about its breast cancer studies; (3) all the foregoing, once revealed, was likely to negatively impact Infinity's business, financial results, and reputation; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/infi, you may also contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Infinity you have until October 16, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson

332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/calling-all-infinity-pharmaceuticals-inc-infi-investors-contact-bronstein-gewirtz--grossman-llc-to-actively-participate-in-the-class-action-lawsuit-301909527.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Mijn selecties